pavinetant pavinetant pavinetant (inn, usan; developmental code names mle-4901, azd-4901, az-12472520, azd-2624), is a small-molecule, orally active, selective neurokinin-3 (nk3) receptor antagonist which was under development by astrazeneca and millendo therapeutics for the treatment of hot flashes and polycystic ovary syndrome (pcos). it was also under investigation for the treatment of schizophrenia, but development was discontinued for this indication due to lack of effectiveness. in november 2017, development of the medication for hot flashes and pcos was also terminated after its developer assessed the clinical risks and benefits. pavinetantclinical dataother namesmle-4901; azd-4901; azd-2624; az-12472520routes ofadministrationby mouthidentifiers iupac name 3-(methanesulfonamido)-2-phenyl-n-quinoline-4-carboxamide cas number941690-55-7pubchem cid23649245chemspider28189763unii3u471zvc5kkeggd11345chebichebi:140478chemblchembl3545233comptox dashboard (epa)dtxsid10916204 chemical and physical dataformulac26h25n3o3smolar mass459.56 g·mol−13d model (jsmol)interactive image smiles cc(c1=cc=cc=c1)nc(=o)c2=c(c(=nc3=cc=cc=c32)c4=cc=cc=c4)ns(=o)(=o)c inchi inchi=1s/c26h25n3o3s/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29h,3h2,1-2h3,(h,28,30)/t21-/m0/s1key:qytbbbahniwfod-nrfanrhfsa-n